.
Biological Dynamics CEO Raj Krishnan and CFO Kevin Han shared what notifies their vision for developing liquid biopsies to identify cancer at the earliest phases to ensure the very best outcome for patients. This Q&A is based on emailed responses to concerns.
Why did you start this business?
My motivation goes back to when I was growing up in the 1990s in the Bay location, where everyone was beginning their own dot com companies. We ended up patenting the innovation and began looking for cancer biomarkers. I didnt simply want to construct a company, I wanted to build a company that could make a real impact in the world.
Kevin: My interest in human health started during my high school years at North Carolina School of Science and Mathematics (NCSSM), where we were exposed to college-level biology classes. It absolutely helped that during this time the Human Genome Project was being conducted, as my interest turned into an enthusiasm and curiosity for disruptive medical innovations. I finished my pre-med requirements at UNC-Chapel Hill and while the thought of helping patients in my regional community was fascinating, I felt that I could make a bigger impact by recommending companies dedicated to the mission of conserving lives, globally.
After my research studies, I took a task with Morgan Stanley and Goldman Sachs to research medical gadget and diagnostics companies and eventually ended up being a financier in the health care area for over a decade. The capability to discover cancer at the earliest phases has the potential to save lives and deliver transformative enhancements to the health care system.
What particular need/problem are you looking for to deal with in healthcare?
Raj Krishnan.
Raj: The earlier you discover cancer, the earlier you can treat cancer. The earlier you deal with cancer, the higher the chance of survival. We desire to focus on early cancer detection, beginning at phase 1A. At Biological Dynamics, we have established a distinct platform to enable early cancer detection, which will offer oncologists the ability to intervene at the earliest stages of illness.
What does your product do? How does it work?
Raj: The difficulty that exists right now with early cancer detection is finding markers in the earliest stages. Current innovations are all limited by the approach utilized to isolate molecules from blood, which often leads to errors. Evaluating these molecules in their native state from an intricate service like blood offers an actually great signal to noise ratio about whether or not cancer might be present.
Is this your very first health care startup? Whats your background in healthcare?
Raj: Yes, this is my very first health care startup. I got my start working at the Moores Cancer Center at UC San Diego.
Kevin Han.
Kevin: Ive been around the health care space for almost 20 years including my early studies and work in epidemiology, specifically studying the metabolic impact of numerous therapies on HIV clients. This capability to touch so numerous patients and impact their lives drew me to the investing side of healthcare. I handled a health care financial investment strategy at different financial investment management firms for over a decade, where I continued to focus on genomics associated companies.
Who is your customer? How do you produce profits?
Any time a client sees their physician for a yearly screening, cholesterol or glucose screening, for example, a small blood sample might also be gathered to screen for cancer. If we are hugely successful, then we can all start to imagine a world, where being diagnosed with cancer at stage 3 or phase 4 is considered an uncommon occasion.
In the health care acquiring decision, such as a diagnostic test, the physician makes the choice which specific test is purchased, while the insurer/government pays for the item, and finally the patient is the one who utilizes the item and/or benefits. Although we view the patient as our final client, we will require the assistance and buy-in from the whole health care system to meet our vision.
In the near-term, we plan to create earnings through the LDT pathway as we have a CLIA lab at our headquarters in San Diego, CA. Throughout the LDT income stage, we want to generate profits from larger self-insured employers and incorporated health networks. Over time, we will pursue an FDA approval, which will be practical to secure reimbursement through both commercial and government payors. The income through both the LDT and FDA paths will be generated through a diagnostics-as-a-service (DaaS) design, which will not require our consumers to buy any devices or need yearly CLIA waivers for our consumers we will operate as a full-service lab, which will minimize friction for our clients while preserving cost scale for ourselves.
Do you have clinical validation for your product?
Raj: Like other ingenious kinds of diagnostic companies, we have to go through a proper regulatory process. Our innovation is not yet FDA authorized, we are releasing information. This data gives us the self-confidence to continue with the commercialization of our product.
Kevin: To support our scientific validation strategies, we are presently in the lasts of a capital raise, which would be utilized for complete analytical validation before setting up a larger scientific utility research study. Our next focus is to launch our item through the LDT pathway and we will commensurately use funds from the present fundraise to support this effort. As you can inform, we are very delighted about the companys objective and we thank our groups for their commitment and assistance!
Image: mathisworks, Getty Images
.

We ended up patenting the innovation and started looking for cancer biomarkers. The ability to find cancer at the earliest stages has the potential to conserve lives and deliver transformative enhancements to the health care system.
Raj: The earlier you find cancer, the earlier you can treat cancer. At Biological Dynamics, we have developed an unique platform to allow early cancer detection, which will give oncologists the ability to intervene at the earliest phases of disease.
If we are extremely effective, then we can all start to think of a world, where being diagnosed with cancer at phase 3 or phase 4 is thought about an unusual occasion.